Brief: Merck KGaA - To Present New Data Highlighting Durable Effects Of Mavenclad® In Rms At Ectrims
17/09/2025 13:20
Sept 17 (Reuters) - Merck KGaA MRCG.DE: MERCK KGAA - TO PRESENT NEW DATA HIGHLIGHTING DURABLE EFFECTS OF MAVENCLAD® IN RMS AT ECTRIMS MERCK KGAA - FOUR-YEAR DATA SHOW NEARLY 9 IN 10 RMS PATIENTS REMAINED FREE FROM PROGRESSION INDEPENDENT OF RELAPSE ACTIVITY (PIRA) Further company coverage: MRCG.DE (Gdansk Newsroom) (((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600);))
Recent news on Merck KGaA
See all newsUS stocks weekly: AI reality
US stocks weekly: AI reality
Brief: Bio-Techne Co Will Be Required To Pay To Merck KGaA Termination Fee Equal To $230.5 Million If Deal Terminated Under Certain Circumstances - SEC Filing
Press Digest: Financial Times - June 26
US STOCKS-Wall St ends mixed as tech megacap declines outweigh upbeat chip outlook